Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT07012031
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
37 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Locally Advanced Lung Non-Small Cell Carcinoma


Metastatic Lung Non-Small Cell Carcinoma


Stage III Lung Cancer AJCC v8


Stage IV Lung Cancer AJCC v8
SUSPENDED
NCT06364410
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
48 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1)
Clinical Stage III Gastric Cancer AJCC v8


Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8


Clinical Stage IV Gastric Cancer AJCC v8


Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8


Locally Advanced Gastric Carcinoma


Locally Advanced Gastroesophageal Junction Adenocarcinoma


Locally Advanced Malignant Solid Neoplasm


Metastatic Gastric Carcinoma


Metastatic Gastroesophageal Junction Adenocarcinoma


Metastatic Malignant Solid Neoplasm


Unresectable Gastric Carcinoma


Unresectable Gastroesophageal Junction Adenocarcinoma


Unresectable Malignant Solid Neoplasm
RECRUITING
NCT06311214
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
500 Enrollment(s)
24 Study location(s)
INTERVENTIONAL (PHASE2)
Advanced Malignant Solid Neoplasm


Metastatic Malignant Solid Neoplasm
ACTIVE_NOT_RECRUITING
NCT04294628
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
62 Enrollment(s)
6 Study location(s)
INTERVENTIONAL (PHASE1)
Advanced Malignant Solid Neoplasm


HER2-Positive Breast Carcinoma


Metastatic Malignant Solid Neoplasm


Refractory Malignant Solid Neoplasm


Unresectable Malignant Solid Neoplasm
RECRUITING
NCT07137416
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
36 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1)
Anatomic Stage III Breast Cancer AJCC v8


Anatomic Stage IV Breast Cancer AJCC v8


Invasive Breast Carcinoma


Locally Advanced Breast Carcinoma


Metastatic Breast Carcinoma


Metastatic HER2-Low Breast Carcinoma


Metastatic HER2-Positive Breast Carcinoma


Metastatic Hormone Receptor-Positive Breast Carcinoma


Metastatic Malignant Solid Neoplasm


Metastatic Triple-Negative Breast Carcinoma


Unresectable Breast Carcinoma


Unresectable HER2-Low Breast Carcinoma


Unresectable HER2-Positive Breast Carcinoma


Unresectable Hormone Receptor-Positive Breast Carcinoma


Unresectable Malignant Solid Neoplasm


Unresectable Triple-Negative Breast Carcinoma
RECRUITING
NCT06764875
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
840 Enrollment(s)
279 Study location(s)
INTERVENTIONAL (PHASE3)
HER2-positive Gastric Cancer


Gastroesophageal Junction Adenocarcinoma
RECRUITING
NCT06650501
Dabigatran vs. Apixaban, Edoxaban, or Rivaroxaban as Anti-thrombotic Therapy in Patients With S. Aureus Bacteremia
300 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
Staphylococcus Aureus Endocarditis


Staphylococcus Aureus Septicemia


Staphylococcus Aureus Bacteremia


Staphylococcus Aureus Bloodstream Infection


S. Aureus Bacteremia


S. Aureus Bloodstream Infection
SUSPENDED
NCT05372614
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
33 Enrollment(s)
18 Study location(s)
INTERVENTIONAL (PHASE1)
Metastatic Malignant Solid Neoplasm


Unresectable Malignant Solid Neoplasm